List of Excipients in Branded Drug FOLLISTIM AQ

« Back to Dashboard

Follistim AQ Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Follistim AQ is a recombinant follitropin beta, or recombinant follicle-stimulating hormone (FSH), used for controlled ovarian stimulation and spermatogenesis induction. Its commercial value is tied less to the active molecule than to delivery-device usability, protein stability, preservative strategy, cartridge manufacturing, and regulatory positioning against Gonal-f and other gonadotropins. The principal excipient opportunity is a differentiated, low-volume, preservation-free or extended-stability presentation supported by formulation, container-closure, device, and manufacturing patents.

What excipients are used in Follistim AQ?

Follistim AQ is supplied as a sterile aqueous recombinant protein formulation for administration through the Follistim Pen. The U.S. prescribing information identifies excipients that include sucrose, sodium citrate, L-methionine, polysorbate 20, benzyl alcohol, and water for injection, depending on the presentation and labeled configuration.[1]

Formulation element	Role in Follistim AQ strategy	Commercial relevance
Sucrose	Stabilizes the recombinant FSH protein during storage and handling	Supports liquid formulation stability without lyophilization
Sodium citrate	Controls pH and ionic environment	Influences protein aggregation, injection tolerability, and container compatibility
L-methionine	Functions as an antioxidant or oxidation-control excipient	Helps protect oxidation-sensitive amino acid residues in the protein
Polysorbate 20	Limits adsorption and interfacial aggregation	Important for cartridge filling, agitation, and device delivery
Benzyl alcohol	Preservative in applicable multidose configurations	Enables multidose use but creates toxicity and labeling considerations
Water for injection	Vehicle	Determines concentration, viscosity, and injection volume

The exact excipient profile must be confirmed against the current U.S. label for the specific cartridge strength and market presentation. Excipient concentrations, preservative status, and container-closure specifications are commercially material because they affect stability, device performance, and regulatory comparability.

What formulation patents protect Follistim AQ?

Follistim AQ protection is likely to involve a layered estate rather than a single composition-of-matter patent. The relevant patent categories are:

1. Recombinant follitropin beta production.
2. Protein purification and impurity control.
3. Aqueous FSH formulations.
4. Stabilization with sugars, surfactants, amino acids, and buffers.
5. Multidose preservation.
6. Cartridge and pen delivery systems.
7. Dose-setting and injection mechanisms.
8. Manufacturing, filling, and storage conditions.
9. Methods of ovarian stimulation or infertility treatment.

Because Follistim AQ is a biologic, its patent position differs from that of a conventional small-molecule drug. The biologic license application is not ordinarily accompanied by an Orange Book patent listing in the same manner as an NDA. A competitor generally would not use an ANDA Paragraph IV certification to enter with a conventional generic version of follitropin beta. A biosimilar applicant would use the Public Health Service Act Section 351(k) pathway and address patents through the Biologics Price Competition and Innovation Act framework.[2]

What excipient claims are commercially defensible?

The strongest excipient claims generally do not cover an isolated, conventional ingredient such as sucrose or polysorbate 20. Those ingredients are widely used in biologics and are vulnerable to prior-art challenges. More defensible claims may combine:

• Follitropin beta at a defined concentration;
• A specified sucrose-to-protein ratio;
• A defined polysorbate concentration;
• A narrow pH range;
• Methionine or another oxidation-control agent;
• Low aggregate formation after storage;
• Defined potency retention;
• Compatibility with a specific cartridge or pen;
• Stability after repeated dose withdrawals;
• A preservative-free multidose configuration.

Patent value increases when a formulation claim is linked to measurable performance, such as reduced subvisible particles, lower aggregate levels, improved potency retention, or reduced adsorption to the primary container.

When does Follistim AQ lose exclusivity?

Follistim AQ’s original regulatory and core technology protections are mature. The principal U.S. commercial risk is therefore not a near-term loss of basic molecule exclusivity but the entry of competing recombinant FSH products, biosimilar products, or alternative gonadotropin regimens.

Exclusivity or protection category	Follistim AQ position
Small-molecule Orange Book exclusivity	Not the principal regulatory framework
Biologic reference-product exclusivity	Original reference-product exclusivity is mature
Composition-of-matter protection	Expected to be expired or commercially weak for the recombinant FSH molecule
Formulation protection	Potentially relevant where claim scope and enforceability remain active
Device protection	Potentially relevant to the Follistim Pen, cartridge, dose-setting, and delivery architecture
Manufacturing protection	Potentially relevant to recombinant production, purification, filling, and quality control
Market exclusivity	Depends on competing follitropin products, contracting, physician preference, and biosimilar approval

An exact patent-by-patent expiration analysis requires a current global patent-family review. The commercially relevant question is whether active claims cover the marketed formulation or only legacy manufacturing and device features.

What is the FDA regulatory status of Follistim AQ?

Follistim AQ is an FDA-approved recombinant follitropin beta product. The product is regulated as a biologic rather than as a conventional generic drug. Its principal U.S. regulatory reference is the FDA-approved prescribing information and biologics license documentation.[1]

The regulatory consequences are significant:

• A conventional ANDA is generally not the expected entry pathway.
• A follow-on applicant would need to pursue a biologics pathway or another applicable biologic approval route.
• Analytical similarity would need to address protein identity, purity, potency, glycosylation, aggregation, and biological activity.
• Clinical development requirements would depend on the FDA’s determination of residual uncertainty.
• Device comparability would be important because dosing is delivered through a dedicated pen and cartridge system.
• Interchangeability would require a separate showing under the applicable biologic standard.

Follitropin beta is also exposed to competition from products containing follitropin alfa. A follitropin alfa product is not automatically a biosimilar to follitropin beta because the reference proteins are different products with potentially different glycosylation profiles and regulatory histories.

How does Follistim AQ compare with competing fertility drugs?

Product	Active ingredient	Delivery or formulation angle	Competitive position
Follistim AQ	Follitropin beta	Cartridge and reusable pen; aqueous recombinant FSH	Strong device familiarity and established IVF use
Gonal-f	Follitropin alfa	Prefilled pen, cartridge, or vial presentations depending on market	Direct recombinant FSH competitor
Menopur	Menotropins	Urinary-derived FSH and LH activity; reconstituted injection	Competes where LH activity is clinically preferred
Bravelle	Urofollitropin	Urinary-derived FSH	Alternative FSH source; product availability varies
Rekovelle	Follitropin delta	Dose individualization based partly on AMH and body weight	Differentiated dosing concept; geographic availability is a factor
Bemfola	Follitropin alfa	Prefilled pen	European recombinant FSH competitor

The most important differentiators are not only FSH activity and dose. They include pen ergonomics, injection volume, dose precision, cold-chain requirements, cartridge waste, training burden, reimbursement, and clinic purchasing agreements.

What excipient opportunities exist for Follistim AQ?

Preservation-free multidose formulation

Benzyl alcohol can support multidose use but creates a potential differentiation point. A preservation-free cartridge with validated in-use stability could reduce preservative exposure and support positioning for sensitive patient populations. The principal technical challenge is microbial control after repeated withdrawals.

A commercially useful patent could claim a multidose recombinant FSH formulation that maintains sterility and potency after repeated pen use without benzyl alcohol. Such claims would need strong supporting data because preservation-free multidose biologics face demanding container-closure and in-use stability requirements.

Higher-concentration formulation

A higher-concentration product could reduce injection volume and improve patient convenience. The formulation must control viscosity, aggregation, adsorption, and dose accuracy. Increasing protein concentration can create problems with:

• Protein-protein interaction;
• Subvisible particles;
• Surface adsorption;
• Pen force;
• Delivered-volume precision;
• Recovery from the cartridge.

A high-concentration formulation patent would be more valuable if it links the excipient system to a specific delivery device and demonstrated stability.

Improved polysorbate strategy

Polysorbate degradation can generate peroxides and fatty-acid degradation products that may affect protein stability. An excipient strategy could focus on low-peroxide polysorbate, controlled degradation products, alternative surfactants, or a defined antioxidant system.

Potential commercial claims include:

• A low-peroxide polysorbate 20 specification;
• A defined peroxide threshold at release and expiry;
• A formulation with methionine or another oxidation-control agent;
• Reduced particle generation during cartridge storage;
• Improved stability after temperature excursions.

Device-compatible formulation

The formulation must operate within the mechanical limits of the Follistim Pen or a competing injector. Relevant variables include viscosity, friction, dead volume, seal extractables, plunger force, and dose reproducibility.

A formulation-device patent could protect a specific combination of:

• Follitropin beta concentration;
• Excipient concentration;
• Cartridge material;
• Stopper or seal composition;
• Pen delivery mechanism;
• Delivered-dose accuracy.

This approach may create a stronger barrier than an excipient-only claim because it ties the formulation to a commercial delivery system.

What manufacturing and IP barriers affect follow-on entry?

A follow-on competitor must reproduce more than the labeled excipient list. It must establish a robust manufacturing process for a complex recombinant glycoprotein. Key barriers include:

1. Stable expression of the FSH alpha and beta subunits.
2. Consistent glycosylation and charge-variant profiles.
3. Removal of host-cell proteins, DNA, and process impurities.
4. Control of aggregates and fragments.
5. Reliable potency assays.
6. Low-particle filling into cartridges.
7. Compatibility between formulation and pen components.
8. Long-term refrigerated stability.
9. Comparability after manufacturing-scale changes.

The commercial barrier is strongest where formulation, filling, and device performance are integrated. A competitor may be able to produce a similar protein but still face development delays if its cartridge produces inconsistent dosing or unacceptable extractables and leachables.

Which companies are challenging Follistim AQ?

The competitive threat is more likely to come from manufacturers of recombinant FSH and fertility biologics than from traditional generic companies. Relevant competitors include Merck Serono, Organon, Ferring Pharmaceuticals, and manufacturers of biosimilar or follow-on gonadotropins in Europe and other regulated markets.

The competitive field has three layers:

• Direct follitropin beta follow-on products;
• Follitropin alfa products competing for the same clinical use;
• Alternative ovarian-stimulation regimens using menotropins, urinary FSH, or newer recombinant gonadotropins.

A 351(k) biosimilar to follitropin beta would face the most direct product-specific competition. Follitropin alfa products create commercial pressure without necessarily creating a direct legal challenge to Follistim AQ’s biologic reference-product status.

What litigation and settlement issues affect Follistim AQ?

A conventional Paragraph IV litigation pathway is not the expected mechanism for Follistim AQ because it is a biologic. The principal legal risks are:

• BPCIA patent-exchange and patent-litigation disputes;
• Formulation patent litigation;
• Cartridge and injector patent litigation;
• Trade-secret disputes involving manufacturing;
• Contract disputes involving regional commercialization rights;
• Patent challenges in Europe and other jurisdictions.

Settlement agreements could delay biosimilar launch, limit launch timing by jurisdiction, or permit entry before the expiration of selected device or formulation patents. A settlement may have limited value if the relevant patents cover only a narrow pen component rather than the protein formulation itself.

What licensing deals create commercial opportunities?

Commercial opportunities include licensing:

• A preservation-free FSH formulation;
• A high-concentration cartridge;
• A next-generation pen;
• A low-waste injector;
• A thermostable formulation;
• A biosimilar-ready cell line or purification platform;
• A combination formulation containing FSH and LH activity.

The most attractive licensing asset is a formulation that reduces cold-chain dependence or improves injection convenience without requiring a completely new device. A formulation compatible with existing pen architecture has a shorter commercialization path than a product requiring a new injector and new human-factors program.

How strong is the Follistim AQ patent estate?

The estate is likely strongest in product integration rather than basic excipient composition. A practical strength assessment is:

Estate component	Relative strength
Recombinant FSH molecule	Low to moderate because of product maturity
Basic sucrose-buffer-surfactant formulation	Low unless narrowly claimed with unexpected results
Specific stability profile	Moderate to strong if supported by comparative data
Cartridge and pen integration	Moderate to strong depending on live claims
Manufacturing process	Moderate where process know-how is difficult to reverse engineer
Preservation-free multidose product	Potentially strong if technically demonstrated
High-concentration formulation	Potentially strong if linked to device and stability performance
Clinical method-of-use claims	Variable and jurisdiction-dependent

What generic launch scenarios exist?

The likely launch scenarios are:

1. A direct follitropin beta biosimilar using a compatible multidose cartridge.
2. A lower-cost follitropin alfa product competing clinically rather than legally.
3. A device-led product with improved dosing, smaller injection volume, or lower waste.
4. A formulation-led product with longer refrigerated shelf life.
5. A regional launch in Europe or emerging markets before U.S. entry.
6. A combination product that competes for the same ovarian-stimulation protocols.

The highest-value commercial opportunity is a follow-on product that combines analytical similarity with a meaningful delivery advantage. Price-only competition would face substantial pressure from established physician and clinic purchasing relationships.

Key Takeaways

• Follistim AQ is a recombinant follitropin beta biologic whose commercial protection is likely concentrated in formulation, cartridge, pen, manufacturing, and device-integration claims.
• The key excipients are sucrose, sodium citrate, L-methionine, polysorbate 20, benzyl alcohol in applicable presentations, and water for injection.
• A conventional ANDA Paragraph IV challenge is not the normal U.S. pathway for this biologic.
• The most attractive formulation opportunities are preservation-free multidose use, higher concentration, lower injection volume, improved surfactant control, and longer stability.
• Follitropin alfa products compete commercially but are not automatically biosimilars to follitropin beta.
• A strong follow-on product would need protein comparability, cartridge compatibility, device precision, and a differentiated commercial proposition.
• The highest-value patent claims are likely to link excipient composition with measurable stability and delivery performance.

FAQs

Can Follistim AQ be copied by making the same excipient formulation?

No. A follow-on product must establish biologic comparability, manufacturing consistency, stability, potency, and device performance. Reproducing the labeled excipients alone would not establish biosimilarity or regulatory substitutability.

Is benzyl alcohol essential to Follistim AQ?

Benzyl alcohol is relevant to applicable multidose presentations, but it is not the only possible preservation strategy. A preservation-free multidose product could create a differentiated commercial and patent opportunity if sterility and in-use stability are demonstrated.

Can a follitropin alfa product replace Follistim AQ legally?

Not automatically. Follitropin alfa and follitropin beta are distinct recombinant FSH products. Clinical substitution, regulatory interchangeability, and reimbursement treatment depend on the applicable jurisdiction and product approvals.

What is the best excipient strategy for a Follistim AQ biosimilar?

The strongest strategy is usually a formulation that preserves protein quality while enabling a differentiated cartridge or pen. High-concentration, low-particle, low-peroxide, preservation-free, and temperature-tolerant systems are more commercially defensible than a simple copy of the reference formulation.

Does Follistim AQ have Orange Book patents?

Follistim AQ is regulated as a biologic, so its U.S. patent and exclusivity analysis does not follow the standard NDA Orange Book model used for small-molecule drugs. Biosimilar applicants generally address relevant patents under the BPCIA framework.

References

1. U.S. Food and Drug Administration. (n.d.). Follistim AQ prescribing information. FDA.
2. U.S. Food and Drug Administration. (2023). Biosimilar and interchangeable biosimilar products. FDA.
3. U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. FDA.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.
5. European Medicines Agency. (n.d.). Fertility medicines and recombinant follicle-stimulating hormone products. EMA.